Global Impact of the COVID-19 Pandemic on Cerebral Venous Thrombosis and Mortality.
COVID-19
Cerebral venous thrombosis
Mortality
SARS-CoV-2
Stroke
Vaccine-induced immune thrombotic thrombocytopenia
Journal
Journal of stroke
ISSN: 2287-6391
Titre abrégé: J Stroke
Pays: Korea (South)
ID NLM: 101602023
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
25
02
2022
accepted:
15
04
2022
entrez:
9
6
2022
pubmed:
10
6
2022
medline:
10
6
2022
Statut:
ppublish
Résumé
Recent studies suggested an increased incidence of cerebral venous thrombosis (CVT) during the coronavirus disease 2019 (COVID-19) pandemic. We evaluated the volume of CVT hospitalization and in-hospital mortality during the 1st year of the COVID-19 pandemic compared to the preceding year. We conducted a cross-sectional retrospective study of 171 stroke centers from 49 countries. We recorded COVID-19 admission volumes, CVT hospitalization, and CVT in-hospital mortality from January 1, 2019, to May 31, 2021. CVT diagnoses were identified by International Classification of Disease-10 (ICD-10) codes or stroke databases. We additionally sought to compare the same metrics in the first 5 months of 2021 compared to the corresponding months in 2019 and 2020 (ClinicalTrials.gov Identifier: NCT04934020). There were 2,313 CVT admissions across the 1-year pre-pandemic (2019) and pandemic year (2020); no differences in CVT volume or CVT mortality were observed. During the first 5 months of 2021, there was an increase in CVT volumes compared to 2019 (27.5%; 95% confidence interval [CI], 24.2 to 32.0; P<0.0001) and 2020 (41.4%; 95% CI, 37.0 to 46.0; P<0.0001). A COVID-19 diagnosis was present in 7.6% (132/1,738) of CVT hospitalizations. CVT was present in 0.04% (103/292,080) of COVID-19 hospitalizations. During the first pandemic year, CVT mortality was higher in patients who were COVID positive compared to COVID negative patients (8/53 [15.0%] vs. 41/910 [4.5%], P=0.004). There was an increase in CVT mortality during the first 5 months of pandemic years 2020 and 2021 compared to the first 5 months of the pre-pandemic year 2019 (2019 vs. 2020: 2.26% vs. 4.74%, P=0.05; 2019 vs. 2021: 2.26% vs. 4.99%, P=0.03). In the first 5 months of 2021, there were 26 cases of vaccine-induced immune thrombotic thrombocytopenia (VITT), resulting in six deaths. During the 1st year of the COVID-19 pandemic, CVT hospitalization volume and CVT in-hospital mortality did not change compared to the prior year. COVID-19 diagnosis was associated with higher CVT in-hospital mortality. During the first 5 months of 2021, there was an increase in CVT hospitalization volume and increase in CVT-related mortality, partially attributable to VITT.
Sections du résumé
BACKGROUND AND PURPOSE
Recent studies suggested an increased incidence of cerebral venous thrombosis (CVT) during the coronavirus disease 2019 (COVID-19) pandemic. We evaluated the volume of CVT hospitalization and in-hospital mortality during the 1st year of the COVID-19 pandemic compared to the preceding year.
METHODS
We conducted a cross-sectional retrospective study of 171 stroke centers from 49 countries. We recorded COVID-19 admission volumes, CVT hospitalization, and CVT in-hospital mortality from January 1, 2019, to May 31, 2021. CVT diagnoses were identified by International Classification of Disease-10 (ICD-10) codes or stroke databases. We additionally sought to compare the same metrics in the first 5 months of 2021 compared to the corresponding months in 2019 and 2020 (ClinicalTrials.gov Identifier: NCT04934020).
RESULTS
There were 2,313 CVT admissions across the 1-year pre-pandemic (2019) and pandemic year (2020); no differences in CVT volume or CVT mortality were observed. During the first 5 months of 2021, there was an increase in CVT volumes compared to 2019 (27.5%; 95% confidence interval [CI], 24.2 to 32.0; P<0.0001) and 2020 (41.4%; 95% CI, 37.0 to 46.0; P<0.0001). A COVID-19 diagnosis was present in 7.6% (132/1,738) of CVT hospitalizations. CVT was present in 0.04% (103/292,080) of COVID-19 hospitalizations. During the first pandemic year, CVT mortality was higher in patients who were COVID positive compared to COVID negative patients (8/53 [15.0%] vs. 41/910 [4.5%], P=0.004). There was an increase in CVT mortality during the first 5 months of pandemic years 2020 and 2021 compared to the first 5 months of the pre-pandemic year 2019 (2019 vs. 2020: 2.26% vs. 4.74%, P=0.05; 2019 vs. 2021: 2.26% vs. 4.99%, P=0.03). In the first 5 months of 2021, there were 26 cases of vaccine-induced immune thrombotic thrombocytopenia (VITT), resulting in six deaths.
CONCLUSIONS
During the 1st year of the COVID-19 pandemic, CVT hospitalization volume and CVT in-hospital mortality did not change compared to the prior year. COVID-19 diagnosis was associated with higher CVT in-hospital mortality. During the first 5 months of 2021, there was an increase in CVT hospitalization volume and increase in CVT-related mortality, partially attributable to VITT.
Identifiants
pubmed: 35677980
pii: jos.2022.00752
doi: 10.5853/jos.2022.00752
pmc: PMC9194544
doi:
Banques de données
ClinicalTrials.gov
['NCT04934020']
Types de publication
Journal Article
Langues
eng
Pagination
256-265Subventions
Organisme : Transilvania University Brasov
Organisme : COST Association
ID : CA18118
Organisme : Ministry of Education, Youth and Sports
ID : LTC20051
Organisme : CZECRIN Large Research Infrastructure
ID : LM2018128
Organisme : Medtronic
Organisme : SVIN
Organisme : Stryker
Organisme : IschemiaView
Organisme : Viz.ai
Organisme : Siemens Foundation
Organisme : National C-VASC COVID-19 Study
Organisme : National Program of Sustainability
ID : LQ1605
Organisme : Bristol-Myers Squibb
Organisme : Medtronic
Organisme : Cerenovus
Organisme : Penumbra
Organisme : Genentech
Références
AJNR Am J Neuroradiol. 2020 Aug;41(8):1370-1376
pubmed: 32554424
Eur J Neurol. 2021 Oct;28(10):3478-3490
pubmed: 33426733
JAMA. 2021 Jul 27;326(4):332-338
pubmed: 34213527
Stroke. 2012 Dec;43(12):3375-7
pubmed: 22996960
AJNR Am J Neuroradiol. 2021 Jul;42(7):1196-1200
pubmed: 33888450
J Stroke Cerebrovasc Dis. 2021 Jan;30(1):105392
pubmed: 33130478
EClinicalMedicine. 2021 Sep;39:101061
pubmed: 34368663
Int J Stroke. 2022 Jan 04;:17474930211066416
pubmed: 35034522
Acta Neurol Belg. 2021 Oct;121(5):1251-1258
pubmed: 34148220
Expert Rev Med Devices. 2021 Jun;18(6):523-531
pubmed: 33966557
J Stroke Cerebrovasc Dis. 2020 Dec;29(12):105412
pubmed: 33254367
Clin Res Cardiol. 2020 Dec;109(12):1540-1548
pubmed: 32749558
Int J Stroke. 2021 Jun;16(4):437-447
pubmed: 32852257
JAMA Neurol. 2022 Jan 1;79(1):22-31
pubmed: 34747975
J Stroke. 2022 May;24(2):179-188
pubmed: 35677974
Int J Stroke. 2021 Jul;16(5):573-584
pubmed: 33459583
JAMA Neurol. 2021 Nov 1;78(11):1314-1323
pubmed: 34581763
Lancet. 2021 Sep 25;398(10306):1147-1156
pubmed: 34370972
Curr Cardiol Rep. 2022 Jan;24(1):43-50
pubmed: 35028817
Stroke Vasc Neurol. 2021 Dec;6(4):542-552
pubmed: 33771936
J Stroke Cerebrovasc Dis. 2021 Jun;30(6):105733
pubmed: 33743411
JAMA Netw Open. 2021 May 3;4(5):e2112131
pubmed: 33974053
Stroke. 2020 Jul;51(7):2002-2011
pubmed: 32432996
Stroke. 2016 Sep;47(9):2180-2
pubmed: 27435401
Stroke. 2020 Oct;51(10):3156-3168
pubmed: 32897811
Neurology. 2020 Oct 20;95(16):e2200-e2213
pubmed: 32847952
Neurology. 2021 Jun 8;96(23):e2824-e2838
pubmed: 33766997
Stroke. 2020 Dec;51(12):3746-3750
pubmed: 33059543
J Thromb Thrombolysis. 2022 Feb;53(2):359-362
pubmed: 34739662
Stroke. 2021 Nov;52(11):e706-e709
pubmed: 34428931
Science. 2022 Jan 21;375(6578):267-269
pubmed: 35050660
Int J Stroke. 2021 Feb;16(2):137-149
pubmed: 33103610
J Neurol Neurosurg Psychiatry. 2022 Apr;93(4):360-368
pubmed: 35078916
Stroke. 2022 Mar;53(3):728-738
pubmed: 35143325
BMC Neurol. 2021 Jan 30;21(1):43
pubmed: 33514335
JAMA. 2021 May 11;325(18):1829-1830
pubmed: 33787821
Stroke. 2021 Aug;52(9):3045-3053
pubmed: 34304601